EXPAREL is now an opioid-free option for use as an interscalene brachial plexus block for upper extremity surgeries Conference call on Monday, April 9, 2018 at 8:30 a.m. EST PARSIPPANY, N.J., April 06 ...

The Food and Drug Administration (FDA) has approved the use of Exparel (bupivacaine liposome injectable suspension; Pacira Pharmaceuticals) as an interscalene brachial plexus block to produce ...

Announcing a new article publication for BIO Integration journal. In this article the authors Daowei Lin, Zhixiao Han, Yanni Fu, Xiaoqiu Zhu, Jin Li, Hui Xu, Jing Wen, Fei Wang and Mingyan Guo from ...

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...

PARSIPPANY, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the publication of its multinational Phase 3 study supporting the efficacy and safety of ...

--EXPAREL is the first long-acting non-opioid option for field block and brachial plexus or femoral nerve block approved in Europe-- “We are pleased to see news of the European Commission’s approval ...

Please provide your email address to receive an email when new articles are posted on . After shoulder surgery, a single-injection of ultrasound-guided brachial plexus block with liposome bupivacaine ...

EXPAREL is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, ...

TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced ...

In summary, the present study shows that ropivacaine 50 mg given around interscalene brachial plexus as 0.25, 0.5 or 0.75 % solution before arthroscopic shoulder surgery produces comparable blockade ...